Vaginal estriol plus viable Lactobacillus acidophilus KS400 	Placebo	Improvement in Vaginal Maturation Index	1046	1190	The Controlled phase results for a change in VMI demonstrated superiority of the 0.03 mg estriol–lactobacilli combination to placebo (p < 0.001)
Vaginal estriol plus viable Lactobacillus acidophilus KS400 	Placebo	Baseline characteristics	15205	15291	Demographic and baseline characteristics were comparable between both treatment groups
Vaginal estriol plus viable Lactobacillus acidophilus KS400 	Placebo	Improvement in Vaginal Maturation Index	1046	1442	The Controlled phase results for a change in VMI demonstrated superiority of the 0.03 mg estriol–lactobacilli combination to placebo (p < 0.001). In the test group, the positive change in VMI was 35.2%, compared to 9.9% in the placebo group. In the Open phase after the initial therapy, the VMI was increased to 55.4% and, during maintenance therapy, it stayed at a comparable level (52.8–49.4%).
